Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
- Interventional
- Recruiting
- NCT04319198
Contact Information
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
The primary objective of this study is to evaluate long-term safety in participants with metastasis solid tumors that are benefitting from continuation with sacituzumab govitecan-hziy.
Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers?
No
- Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study
- Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy
Key Exclusion Criteria:
- Females who are pregnant or lactating
- Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated
- Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy
- Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
- Metastatic Cancer
- Solid Tumors